DNAJC2
gene geneOn this page
Also known as MPP11MPHOSPH11ZUO1zuotin
Summary
DNAJC2 (DnaJ heat shock protein family (Hsp40) member C2, HGNC:13192) is a protein-coding gene on chromosome 7q22.1, encoding DnaJ homolog subfamily C member 2 (Q99543). Acts both as a chaperone in the cytosol and as a chromatin regulator in the nucleus.
This gene is a member of the M-phase phosphoprotein (MPP) family. The gene encodes a phosphoprotein with a J domain and a Myb DNA-binding domain which localizes to both the nucleus and the cytosol. The protein is capable of forming a heterodimeric complex that associates with ribosomes, acting as a molecular chaperone for nascent polypeptide chains as they exit the ribosome. This protein was identified as a leukemia-associated antigen and expression of the gene is upregulated in leukemic blasts. Also, chromosomal aberrations involving this gene are associated with primary head and neck squamous cell tumors. This gene has a pseudogene on chromosome 6. Alternatively spliced variants which encode different protein isoforms have been described.
Source: NCBI Gene 27000 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 84 total
- GTEx eGene: eQTL in 11 tissues, sQTL in 0 (q < 0.05)
- Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.47 (moderately constrained)
- MANE Select transcript:
NM_014377 - Interaction hub: 2,022 STRING partners (top 7% of genes corpus-wide)
- Notable: 84 clinical variants but no curated precision-oncology (CIViC) evidence yet
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:13192 |
| Approved symbol | DNAJC2 |
| Name | DnaJ heat shock protein family (Hsp40) member C2 |
| Location | 7q22.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MPP11, MPHOSPH11, ZUO1, zuotin |
| Ensembl gene | ENSG00000105821 |
| Ensembl biotype | protein_coding |
| OMIM | 605502 |
| Entrez | 27000 |
Gene structure
Transcript identifiers
Ensembl transcripts: 17 — 8 protein_coding, 5 retained_intron, 4 nonsense_mediated_decay
MANE Select: ENST00000379263
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 6, TSL 2: 1, TSL 3: 1, TSL 5: 3
ENST00000379263, ENST00000249270, ENST00000379257, ENST00000412522, ENST00000426036, ENST00000454277, ENST00000464253, ENST00000475065, ENST00000475090, ENST00000483637, ENST00000492497, ENST00000915316, ENST00001017200, ENST00001017201, ENST00001058857, ENST00001129054, ENST00001142962
RefSeq mRNA: 4 — MANE Select: NM_014377
NM_001129887, NM_001362667, NM_001362668, NM_014377
CCDS: CCDS43628, CCDS47679
Canonical transcript exons
ENST00000379263 — 17 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000881669 | 103341764 | 103341954 |
| ENSE00001530457 | 103344559 | 103344767 |
| ENSE00001600304 | 103322511 | 103322632 |
| ENSE00001628196 | 103322703 | 103322794 |
| ENSE00003460086 | 103326543 | 103326684 |
| ENSE00003464847 | 103312289 | 103312643 |
| ENSE00003497042 | 103315988 | 103316088 |
| ENSE00003500195 | 103316830 | 103317014 |
| ENSE00003501070 | 103327656 | 103327754 |
| ENSE00003594972 | 103337736 | 103337811 |
| ENSE00003613992 | 103323598 | 103323663 |
| ENSE00003625802 | 103312947 | 103313101 |
| ENSE00003628578 | 103315764 | 103315871 |
| ENSE00003650531 | 103321932 | 103322081 |
| ENSE00003656999 | 103319609 | 103319678 |
| ENSE00003671914 | 103319756 | 103319844 |
| ENSE00003686219 | 103324482 | 103324562 |
Expression profiles
Bgee: expression breadth ubiquitous, 296 present calls, max score 96.10.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.4374 / max 383.0341, expressed in 1819 samples.
Highest expression (Bgee): sural nerve, tendon of biceps brachii, gluteal muscle, nasal cavity epithelium, cartilage tissue.
Genetic regulation across tissues (GTEx eQTL / sQTL)
DNAJC2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 11 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
11 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Testis | eqtl | 7.5e-24 | -0.35 | 7:103344764:C:G |
| Muscle Skeletal | eqtl | 1.8e-08 | +0.10 | 7:103344764:C:G |
| Thyroid | eqtl | 4.3e-04 | +0.12 | 7:103307593:T:C |
| Cells Cultured fibroblasts | eqtl | 7.5e-03 | -0.10 | 7:103159690:T:C |
| Whole Blood | eqtl | 8.9e-03 | -0.22 | 7:104084676:A:G |
| Brain Caudate basal ganglia | eqtl | 1.2e-02 | +0.37 | 7:102633821:C:T |
| Brain Frontal Cortex BA9 | eqtl | 2.8e-02 | +0.43 | 7:103539663:G:A |
| Prostate | eqtl | 3.1e-02 | +0.64 | 7:104010968:G:A |
| Esophagus Gastroesophageal Junction | eqtl | 3.7e-02 | -0.23 | 7:103181620:T:G |
| Brain Hippocampus | eqtl | 3.8e-02 | -1.10 | 7:103512901:G:A |
| Skin Sun Exposed Lower leg | eqtl | 4.0e-02 | -0.44 | 7:103940314:A:C |
FANTOM5 promoters
2 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 85375 | 27.6253 | 1817 |
| 85376 | 1.8121 | 944 |
Top tissues by expression
showing 100 of 297 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| sural nerve | UBERON:0015488 | 96.10 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 94.33 | gold quality |
| gluteal muscle | UBERON:0002000 | 93.92 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 93.77 | gold quality |
| cartilage tissue | UBERON:0002418 | 93.47 | gold quality |
| hair follicle | UBERON:0002073 | 93.45 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 93.43 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 93.38 | gold quality |
| tendon | UBERON:0000043 | 93.09 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 92.90 | gold quality |
| cervix epithelium | UBERON:0004801 | 92.42 | gold quality |
| calcaneal tendon | UBERON:0003701 | 92.39 | gold quality |
| sperm | CL:0000019 | 92.24 | gold quality |
| monocyte | CL:0000576 | 92.05 | gold quality |
| mononuclear cell | CL:0000842 | 92.03 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 92.02 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 92.00 | gold quality |
| superficial temporal artery | UBERON:0001614 | 92.00 | gold quality |
| male germ cell | CL:0000015 | 91.99 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 91.96 | gold quality |
| left testis | UBERON:0004533 | 91.89 | gold quality |
| testis | UBERON:0000473 | 91.84 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 91.79 | gold quality |
| mucosa of urinary bladder | UBERON:0001259 | 91.78 | gold quality |
| gastrocnemius | UBERON:0001388 | 91.55 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 91.45 | gold quality |
| leukocyte | CL:0000738 | 91.44 | gold quality |
| oviduct epithelium | UBERON:0004804 | 91.36 | gold quality |
| colonic epithelium | UBERON:0000397 | 91.29 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 91.28 | gold quality |
| right testis | UBERON:0004534 | 91.17 | gold quality |
| colonic mucosa | UBERON:0000317 | 91.02 | gold quality |
| deltoid | UBERON:0001476 | 91.02 | gold quality |
| bone marrow | UBERON:0002371 | 90.72 | gold quality |
| muscle of leg | UBERON:0001383 | 90.52 | gold quality |
| parotid gland | UBERON:0001831 | 90.48 | gold quality |
| myocardium | UBERON:0002349 | 90.47 | gold quality |
| pericardium | UBERON:0002407 | 90.47 | gold quality |
| biceps brachii | UBERON:0001507 | 90.38 | gold quality |
| body of pancreas | UBERON:0001150 | 90.34 | gold quality |
| cortical plate | UBERON:0005343 | 90.31 | gold quality |
| adrenal tissue | UBERON:0018303 | 90.27 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 90.23 | gold quality |
| muscle organ | UBERON:0001630 | 90.20 | gold quality |
| triceps brachii | UBERON:0001509 | 90.07 | gold quality |
| endometrium | UBERON:0001295 | 90.06 | gold quality |
| ventricular zone | UBERON:0003053 | 89.96 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 89.96 | gold quality |
| embryo | UBERON:0000922 | 89.89 | gold quality |
| heart right ventricle | UBERON:0002080 | 89.70 | gold quality |
| jejunum | UBERON:0002115 | 89.48 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 89.46 | gold quality |
| left ovary | UBERON:0002119 | 89.45 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 89.45 | gold quality |
| ovary | UBERON:0000992 | 89.41 | gold quality |
| fallopian tube | UBERON:0003889 | 89.37 | gold quality |
| tonsil | UBERON:0002372 | 89.34 | gold quality |
| uterine cervix | UBERON:0000002 | 89.33 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 89.33 | gold quality |
| rectum | UBERON:0001052 | 89.30 | gold quality |
| tibia | UBERON:0000979 | 89.29 | gold quality |
| skin of abdomen | UBERON:0001416 | 89.29 | gold quality |
| right ovary | UBERON:0002118 | 89.22 | gold quality |
| jejunal mucosa | UBERON:0000399 | 89.20 | gold quality |
| lymph node | UBERON:0000029 | 89.17 | gold quality |
| vastus lateralis | UBERON:0001379 | 89.12 | gold quality |
| quadriceps femoris | UBERON:0001377 | 89.08 | gold quality |
| ganglionic eminence | UBERON:0004023 | 89.05 | gold quality |
| uterus | UBERON:0000995 | 88.96 | gold quality |
| placenta | UBERON:0001987 | 88.95 | gold quality |
| adenohypophysis | UBERON:0002196 | 88.91 | gold quality |
| zone of skin | UBERON:0000014 | 88.87 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 88.87 | gold quality |
| skin of leg | UBERON:0001511 | 88.85 | gold quality |
| epithelium of bronchus | UBERON:0002031 | 88.85 | gold quality |
| muscle tissue | UBERON:0002385 | 88.85 | gold quality |
| bronchus | UBERON:0002185 | 88.80 | gold quality |
| superior surface of tongue | UBERON:0007371 | 88.75 | gold quality |
| peritoneum | UBERON:0002358 | 88.70 | gold quality |
| female reproductive system | UBERON:0000474 | 88.69 | gold quality |
| omental fat pad | UBERON:0010414 | 88.69 | gold quality |
| pancreas | UBERON:0001264 | 88.64 | gold quality |
| parietal pleura | UBERON:0002400 | 88.61 | gold quality |
| tibialis anterior | UBERON:0001385 | 88.59 | gold quality |
| gingival epithelium | UBERON:0001949 | 88.59 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 88.59 | gold quality |
| duodenum | UBERON:0002114 | 88.58 | gold quality |
| minor salivary gland | UBERON:0001830 | 88.57 | gold quality |
| bone marrow cell | CL:0002092 | 88.55 | gold quality |
| visceral pleura | UBERON:0002401 | 88.55 | gold quality |
| pylorus | UBERON:0001166 | 88.51 | gold quality |
| bronchial epithelial cell | CL:0002328 | 88.47 | gold quality |
| pleura | UBERON:0000977 | 88.47 | gold quality |
| mouth mucosa | UBERON:0003729 | 88.43 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 88.42 | gold quality |
| vermiform appendix | UBERON:0001154 | 88.31 | gold quality |
| sigmoid colon | UBERON:0001159 | 88.30 | gold quality |
| granulocyte | CL:0000094 | 88.28 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 88.28 | gold quality |
| urinary bladder | UBERON:0001255 | 88.27 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7606 | no | 1175.72 |
| E-MTAB-11011 | no | 229.98 |
| E-MTAB-6386 | no | 142.11 |
| E-ANND-3 | no | 0.00 |
HPA expression
RNA tissue specificity: Low tissue specificity
showing 60 of 80 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Bone marrow | tissue | 39.6 | medium |
| Caudate putamen | tissue | 38.1 | |
| Testis | tissue | 29.3 | high |
| Frontal cortex | tissue | 23.5 | |
| Putamen | tissue | 23.4 | |
| Basal ganglia | tissue | 18.6 | medium |
| Urinary bladder | tissue | 17.5 | high |
| Postcentral gyrus | tissue | 15.8 | |
| Lymph node | tissue | 15.7 | high |
| Nucleus accumbens | tissue | 15.0 | |
| Choroid plexus | tissue | 15.0 | |
| Septum | tissue | 15.0 | |
| Ventral forebrain | tissue | 14.7 | |
| Liver | tissue | 14.6 | medium |
| Cerebral cortex | tissue | 14.5 | high |
| Occipital cortex | tissue | 14.5 | |
| Skeletal muscle | tissue | 14.2 | low |
| Locus coeruleus | tissue | 14.1 | |
| Prefrontal cortex | tissue | 13.9 | |
| Duodenum | tissue | 13.8 | high |
| Hippocampal formation | tissue | 13.7 | |
| Motor cortex | tissue | 13.5 | |
| Retrosplenial and cingulate cortex | tissue | 13.2 | |
| Somatosensory cortex | tissue | 13.2 | |
| Cerebellum | tissue | 13.1 | high |
| Olfactory bulb | tissue | 12.8 | |
| Retrosplenial cortex | tissue | 12.7 | |
| Pancreas | tissue | 12.5 | high |
| Temporal cortex | tissue | 12.5 | |
| Hippocampus | tissue | 12.4 | high |
| Tonsil | tissue | 12.4 | high |
| Entorhinal cortex | tissue | 12.4 | |
| Stomach 1 | tissue | 12.1 | |
| Breast | tissue | 11.9 | medium |
| Hypothalamus | tissue | 11.9 | |
| Tongue | tissue | 11.8 | |
| Pons | tissue | 11.6 | |
| Skin 1 | tissue | 11.5 | high |
| Vagina | tissue | 11.5 | medium |
| Substantia nigra | tissue | 11.5 | |
| Thyroid gland | tissue | 11.5 | high |
| Thymus | tissue | 11.5 | |
| Appendix | tissue | 11.5 | high |
| Pituitary gland | tissue | 11.4 | |
| Amygdala | tissue | 11.4 | |
| Midbrain | tissue | 11.4 | |
| Spinal cord | tissue | 11.4 | |
| Placenta | tissue | 11.2 | high |
| Rectum | tissue | 11.1 | high |
| Small intestine | tissue | 11.1 | high |
| Spleen | tissue | 11.0 | high |
| Endometrium 1 | tissue | 10.8 | high |
| Medulla oblongata | tissue | 10.8 | |
| Periaqueductal gray | tissue | 10.7 | |
| Colon | tissue | 10.4 | high |
| Thalamus | tissue | 10.4 | |
| Superior colliculi | tissue | 10.4 | |
| Insular cortex | tissue | 10.4 | |
| Adrenal gland | tissue | 10.2 | high |
| Ovary | tissue | 10.1 | high |
Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Vermis (19.1), Flocculonodular lobe (18.9), Cerebellar cortex (17.7), Temporal white matter (17.4), Parieto-temporal junction (white matter) (17.1).
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
1 targets:
| Target | Regulation |
|---|---|
| PRC1 |
Functional genomics
gnomAD constraint: pLI 0.997, LOEUF 0.466, missense Z 2.17 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD)
ENST00000379263 splits into 2 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD
| Region (GRCh38) | Missense obs / exp | o/e | Constrained |
|---|---|---|---|
| 7:103,312,572–103,319,843 | 271 / 302.6 | 0.90 | no |
| 7:103,319,844–103,344,622 | 279 / 416.9 | 0.67 | no |
Literature-anchored findings (GeneRIF, showing 16)
- concluded that Mpp11, an ortholog of yeast Zuo, is a ribosome-associated J protein; proposed that in metazoans, ribosome-associated Zuo and Mpp11 orthologs recruit cytosolic Hsc70 to short ribosome-bound nascent chains as they exit the ribosome (PMID:15802566)
- MPP11 is localized to the cytosol and with Hsp70L1, forms the mammalian ribosome-associated complex. (PMID:16002468)
- describe a novel epitope derived from the MPP11 antigen that has been recognized by human CD8+ CTL (PMID:20231810)
- At the onset of differentiation, ZRF1 specifically displaces polycomb-repressive complex 1 (PRC1) from chromatin and facilitates transcriptional activation (PMID:21179169)
- the majority of AML patients elicited a humoral immune response against the tumor antigen MPP11 (PMID:22433847)
- ZRF1 regulates the INK4-ARF locus during cellular proliferation and senescence, and alterations in ZRF1 may contribute to tumorigenesis. (PMID:22733129)
- our data reveal that ZRF1 is a key transcriptional regulator in leukemia progression (PMID:24292673)
- Zrf1 plays an essential role in neural progenitor cell generation and maintenance (PMID:24449271)
- Zrf1 is transcriptional regulator of neural fate downstream of Id1 in embryonic stem cells.During embryonic stem cell differentiation, Id1 levels decrease allowing Zrf1 to activate neural genes. (PMID:25361733)
- ZRF1 mediates remodeling of this E3 ligase complex directly at the DNA lesion site. (PMID:27091446)
- Unexplored functions of ZRF1-mediated remodeling in replication and double strand break repair are discussed. (PMID:27599465)
- The antibody response to ZRF1 was higher in sera of patients with invasive ductal carcinoma than in sera of patients with other histological types of breast tumors. (PMID:27847402)
- In response to UV irradiation, DICER is recruited to chromatin in a ZRF1-mediated manner. The H2A-ubiquitin binding protein ZRF1 and DICER together impact on the chromatin conformation via PARP1. (PMID:28402505)
- These findings suggest that ZRF1 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in gastric cancer (PMID:29228320)
- DNAJC2 is reversely regulated by miR6273p, promoting the proliferation of colorectal cancer. (PMID:34165158)
- p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation. (PMID:34579723)
Cross-species orthologs
11 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | dnajc2 | ENSDARG00000070477 |
| mus_musculus | Dnajc2 | ENSMUSG00000029014 |
| rattus_norvegicus | Dnajc2 | ENSRNOG00000012392 |
| drosophila_melanogaster | CG10565 | FBGN0037051 |
| drosophila_melanogaster | l(3)80Fg | FBGN0287183 |
| caenorhabditis_elegans | WBGENE00001020 | |
| caenorhabditis_elegans | WBGENE00001025 | |
| caenorhabditis_elegans | WBGENE00001026 | |
| caenorhabditis_elegans | WBGENE00001029 | |
| caenorhabditis_elegans | dnj-28 | WBGENE00001046 |
| caenorhabditis_elegans | WBGENE00008122 |
Paralogs (20): DNAJC11 (ENSG00000007923), DNAJC25 (ENSG00000059769), DNAJC10 (ENSG00000077232), DNAJC5 (ENSG00000101152), DNAJC3 (ENSG00000102580), DNAJC17 (ENSG00000104129), DNAJC12 (ENSG00000108176), DNAJC4 (ENSG00000110011), DNAJC16 (ENSG00000116138), DNAJC14 (ENSG00000135392), DNAJC1 (ENSG00000136770), DNAJC13 (ENSG00000138246), DNAJC5B (ENSG00000147570), DNAJC5G (ENSG00000163793), DNAJC7 (ENSG00000168259), DNAJC21 (ENSG00000168724), DNAJC18 (ENSG00000170464), DNAJC24 (ENSG00000170946), DNAJC30 (ENSG00000176410), DNAJC9 (ENSG00000213551)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:99470) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 6 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| decreased circulating calcium level | 1 |
| increased leukocyte cell number | 1 |
| increased circulating triglyceride level | 1 |
| embryonic lethality at implantation, complete penetrance | 1 |
| preweaning lethality, complete penetrance | 1 |
| embryonic lethality prior to organogenesis | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Macaca fascicularis | Q4R8H2 | 98.7% | Diamond |
| Bos taurus | Q1RMH9 | 97.7% | Diamond |
| Xenopus tropicalis | Q6P2Y3 | 84.4% | Diamond |
| Arabidopsis thaliana | Q1G3C4 | 74.7% | Diamond |
| Antirrhinum majus | Q8S9H7 | 71.8% | Diamond |
| Schizosaccharomyces pombe 972h- | Q9Y7I8 | 50.3% | Diamond |
| Saccharomyces cerevisiae S288C | P32527 | 50.2% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| SLC26A5-AS1 | ncRNA | 101927870 |
| SLC26A5 | protein-coding | 375611 |
| RELN | protein-coding | 5649 |
| PSMC2 | protein-coding | 5701 |
| PMPCB | protein-coding | 9512 |
| ORC5 | protein-coding | 5001 |
| FBXL13 | protein-coding | 222235 |
| NAPEPLD | protein-coding | 222236 |
| NFE4 | ncRNA | 58160 |
| ARMC10 | protein-coding | 83787 |
Protein
Protein identifiers
DnaJ homolog subfamily C member 2 — Q99543 (reviewed: Q99543)
Alternative names: M-phase phosphoprotein 11, Zuotin-related factor 1
All UniProt accessions (5): C9IZ83, Q99543, F2Z3H0, F2Z3N9, H7C3L7
UniProt curated annotations — full annotation on UniProt →
Function. Acts both as a chaperone in the cytosol and as a chromatin regulator in the nucleus. When cytosolic, acts as a molecular chaperone: component of the ribosome-associated complex (RAC), a complex involved in folding or maintaining nascent polypeptides in a folding-competent state. In the RAC complex, stimulates the ATPase activity of the ribosome-associated pool of Hsp70-type chaperones HSPA14 that bind to the nascent polypeptide chain. When nuclear, mediates the switching from polycomb-repressed genes to an active state: specifically recruited at histone H2A ubiquitinated at ‘Lys-119’ (H2AK119ub), and promotes the displacement of the polycomb PRC1 complex from chromatin, thereby facilitating transcription activation.
Subunit / interactions. Component of ribosome-associated complex (RAC), a heterodimer composed of Hsp70/DnaK-type chaperone HSPA14 and Hsp40/DnaJ-type chaperone DNAJC2. Interacts (via ZRF1-UBD region) with ID1.
Subcellular location. Nucleus. Cytoplasm. Cytosol.
Tissue specificity. Widely expressed.
Post-translational modifications. Phosphorylated in M (mitotic) phase.
Domain organisation. The ZRF1-UBD region specifically recognizes and binds H2AK119ub. The ZRF1-UBD region is also involved in protein-protein interactions with other proteins, suggesting that it may be masked by some regulator, thereby preventing its association with H2AK119ub.
Induction. Expression is repressed by CEBPA. Strongly overexpressed in leukemic cells.
Miscellaneous. Constitutes a myeloid leukemia-associated antigen and might be a target for leukemia T-cell therapy.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q99543-1 | 1 | yes |
| Q99543-2 | 2 |
RefSeq proteins (4): NP_001123359, NP_001349596, NP_001349597, NP_055192* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001005 | SANT/Myb | Domain |
| IPR001623 | DnaJ_domain | Domain |
| IPR009057 | Homeodomain-like_sf | Homologous_superfamily |
| IPR017884 | SANT_dom | Domain |
| IPR017930 | Myb_dom | Domain |
| IPR018253 | DnaJ_domain_CS | Conserved_site |
| IPR032003 | RAC_head | Domain |
| IPR036869 | J_dom_sf | Homologous_superfamily |
| IPR042569 | RAC_head_sf | Homologous_superfamily |
| IPR044634 | Zuotin/DnaJC2 | Family |
| IPR054076 | ZUO1-like_ZHD | Domain |
Pfam: PF00226, PF16717, PF21884, PF23082
UniProt features (28 total): helix 7, modified residue 5, region of interest 4, sequence conflict 3, domain 3, chain 2, initiator methionine 1, splice variant 1, mutagenesis site 1, turn 1
Structure
Experimental structures (PDB)
2 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 2M2E | Solution NMR structure of the SANT domain of human DNAJC2, Northeast structural genomics … | SOLUTION NMR | |
| 6CGH | Solution structure of the four-helix bundle region of human J-protein Zuotin, a component … | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q99543-F1 | 85.51 | 0.56 |
Human Protein Atlas
Protein class: Predicted intracellular proteins, Plasma proteins, Transcription factors, Helix-turn-helix domains, Cancer-related genes, Candidate cancer biomarkers
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): cytosol
Antibody reliability (HPA): IH approved · IF supported
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (5)
| Type | Positions |
|---|---|
| N-acetylmethionine | 1 |
| Phosphoserine | 47, 49, 60, 63 |
Mutagenesis-validated functional residues (1)
| Position | Phenotype |
|---|---|
| 512–513 | loss of function. |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 4; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
4 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-3371556 | Cellular response to heat stress | — |
| R-HSA-8953897 | Cellular responses to stimuli | — |
| R-HSA-2262752 | Cellular responses to stress | — |
| R-HSA-3371453 | Regulation of HSF1-mediated heat shock response | — |
MSigDB gene sets: 173 (showing top):
RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_HEAT, PUJANA_CHEK2_PCC_NETWORK, GOBP_PROTEIN_MATURATION, ONKEN_UVEAL_MELANOMA_UP, GOBP_NEGATIVE_REGULATION_OF_DNA_BIOSYNTHETIC_PROCESS, DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, DER_IFN_BETA_RESPONSE_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, GOBP_PROTEIN_FOLDING, GOBP_DNA_BIOSYNTHETIC_PROCESS, GOBP_CELLULAR_RESPONSE_TO_HEAT, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS
GO Biological Process (7): DNA-templated transcription (GO:0006351), regulation of translational fidelity (GO:0006450), protein folding (GO:0006457), positive regulation of DNA-templated transcription (GO:0045893), ‘de novo’ cotranslational protein folding (GO:0051083), regulation of cellular response to heat (GO:1900034), chromatin organization (GO:0006325)
GO Molecular Function (8): ATPase activator activity (GO:0001671), chromatin binding (GO:0003682), RNA binding (GO:0003723), Hsp70 protein binding (GO:0030544), histone binding (GO:0042393), ribosome binding (GO:0043022), ubiquitin-modified histone reader activity (GO:0061649), protein binding (GO:0005515)
GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), cytosol (GO:0005829)
Reactome top-level categories
3 top-level categories:
| Category | Pathways |
|---|---|
| Cellular response to heat stress | 1 |
| Cellular responses to stimuli | 1 |
| Cellular responses to stress | 1 |
GO top-level categories
28 GO namespaces:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| binding | 2 |
| nuclear lumen | 2 |
| gene expression | 1 |
| RNA biosynthetic process | 1 |
| regulation of biological quality | 1 |
| cellular process | 1 |
| protein maturation | 1 |
| DNA-templated transcription | 1 |
| regulation of DNA-templated transcription | 1 |
| positive regulation of RNA biosynthetic process | 1 |
| ‘de novo’ protein folding | 1 |
| cellular response to heat | 1 |
| regulation of cellular response to stress | 1 |
| cellular component organization | 1 |
| ATP-dependent activity | 1 |
| molecular function activator activity | 1 |
| nucleic acid binding | 1 |
| heat shock protein binding | 1 |
| protein-folding chaperone binding | 1 |
| protein binding | 1 |
| ribonucleoprotein complex binding | 1 |
| ubiquitin-modified protein reader activity | 1 |
| histone reader activity | 1 |
| intracellular membrane-bounded organelle | 1 |
| intracellular membraneless organelle | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 10 of 20 annotations. The rest are phylogenetic / computational / electronic (IEA).
10 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| positive regulation of DNA-templated transcription | BP | direct assay |
| cytoplasm | CC | direct assay |
| cytosol | CC | direct assay |
| nucleolus | CC | direct assay |
| nucleus | CC | direct assay |
| Hsp70 protein binding | MF | physical interaction |
| RNA binding | MF | high-throughput assay |
| chromatin binding | MF | direct assay |
| histone binding | MF | direct assay |
| ubiquitin-modified histone reader activity | MF | direct assay |
Protein interactions and networks
STRING
showing 15 of 2,022 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| DNAJC2 | DNAJB4 | Q9UDY4 | 952 |
| DNAJC2 | HSPA4 | P34932 | 919 |
| DNAJC2 | DNAJB1 | P25685 | 891 |
| DNAJC2 | HSPA14 | Q0VDF9 | 891 |
| DNAJC2 | DNAJC24 | Q6P3W2 | 871 |
| DNAJC2 | SEC63 | Q9UGP8 | 852 |
| DNAJC2 | DNAJC19 | Q96DA6 | 833 |
| DNAJC2 | HSCB | Q8IWL3 | 821 |
| DNAJC2 | BLZF1 | Q9H2G9 | 775 |
| DNAJC2 | HSPA8 | P11142 | 650 |
| DNAJC2 | ZPR1 | O75312 | 619 |
| DNAJC2 | MYB | P10242 | 583 |
| DNAJC2 | CCNB1 | P14635 | 551 |
| DNAJC2 | DNAJC9 | Q8WXX5 | 538 |
| DNAJC2 | DNAJA1 | P31689 | 519 |
IntAct
Human interaction partners of DNAJC2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
5 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| HSPA14 | physical association | 0.670 | 3 |
| H2AC11 | physical association | 0.500 | 1 |
| H2BC10 | physical association | 0.400 | 1 |
| ID1 | physical association | 0.400 | 1 |
| RPS3A | association | 0.350 | 1 |
BioGRID (288 interactions; top human partners by supporting records): HSPA14 (Co-fractionation; 12 records), DRG1 (Affinity Capture-Western; 6 records), DRG2 (Affinity Capture-Western; 5 records), DICER1 (Proximity Label-MS; 3 records), RPL30 (Affinity Capture-MS; 3 records), RWDD1 (Affinity Capture-MS; 3 records), ZC3H15 (Affinity Capture-MS; 3 records), GNL3 (Affinity Capture-MS; 2 records), GTF2E2 (Affinity Capture-MS; 2 records), H1FX (Affinity Capture-MS; 2 records), HIST2H2AA3 (Affinity Capture-Western; 2 records), HSPA8 (Co-fractionation; 2 records), LTV1 (Proximity Label-MS; 2 records), MTDH (Affinity Capture-MS; 2 records), PPP6R1 (Affinity Capture-MS; 2 records)
SIGNOR signaling
1 signaling interactions:
| A | Effect | B | Mechanism |
|---|---|---|---|
| DNAJC2 | “form complex” | “Ribosome-associated complex” | binding |
Disease & clinical
Genetic variants
Variant evidence for DNAJC2: 84 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.
ClinVar
84 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 62 |
| Likely benign | 0 |
| Benign | 1 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 25 predictions of 1,128):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 7:103312937 | donor_gain | 1.0000 | |
| 7:103315762–103315763 | donor_loss | 1.0000 | 5 |
| 7:103315873 | acceptor_loss | 1.0000 | |
| 7:103315879 | acceptor_gain | 1.0000 | |
| 7:103316046 | acceptor_gain | 1.0000 | |
| 7:103319607–103319608 | donor_loss | 1.0000 | 5 |
| 7:103321930–103321931 | donor_loss | 1.0000 | 4 |
| 7:103321955 | donor_gain | 1.0000 | |
| 7:103321960 | donor_gain | 1.0000 | |
| 7:103322082–103322083 | acceptor_loss | 1.0000 | 5 |
AlphaMissense
1,684 missense substitutions predicted likely pathogenic (of 4,130 scored), across 395 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D121 | 8 | 0.998 | 0.999 |
| H119 | 8 | 0.997 | 1.000 |
| D277 | 8 | 0.996 | 0.998 |
| N251 | 8 | 0.995 | 0.999 |
| D231 | 8 | 0.990 | 0.998 |
| D271 | 8 | 0.990 | 0.999 |
| H487 | 8 | 0.982 | 1.000 |
| F138 | 8 | 0.981 | 0.999 |
| D161 | 8 | 0.981 | 0.994 |
| D88 | 8 | 0.976 | 0.997 |
| D136 | 8 | 0.974 | 0.993 |
| F469 | 8 | 0.970 | 0.999 |
| F214 | 8 | 0.933 | 0.992 |
| S159 | 8 | 0.931 | 0.999 |
| H118 | 8 | 0.925 | 0.999 |
| H89 | 8 | 0.896 | 0.991 |
| N189 | 8 | 0.892 | 0.996 |
| F186 | 8 | 0.888 | 0.993 |
| F164 | 8 | 0.837 | 0.989 |
| W477 | 7 | 1.000 | 1.000 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
2 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Liver Hepatocellular Carcinoma (TCGA) | unfavorable | 4.66e-05 |
| Liver Hepatocellular Carcinoma (validation) | unfavorable | 0.00049 |
Disease associations
OMIM: gene MIM:605502 | disease phenotypes:
GWAS associations
1 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST009391_869 | Metabolite levels | 9e-6 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0010402 | triacylglycerol 46:2 measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
40 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | affects expression, decreases expression | 2 |
| sodium arsenite | increases activity, affects cotreatment, increases abundance, increases expression, decreases expression | 2 |
| Estradiol | increases expression | 2 |
| Tobacco Smoke Pollution | increases expression | 2 |
| Cyclosporine | increases expression | 2 |
| GSK-J4 | increases expression | 1 |
| FR900359 | affects phosphorylation | 1 |
| dicrotophos | decreases expression | 1 |
| methylmercuric chloride | increases expression | 1 |
| trichostatin A | affects expression | 1 |
| cobaltous chloride | increases expression | 1 |
| manganese chloride | affects cotreatment, increases abundance, increases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| 2,3,5-(triglutathion-S-yl)hydroquinone | increases ADP-ribosylation | 1 |
| perfluoro-n-nonanoic acid | increases expression | 1 |
| ICG 001 | decreases expression | 1 |
| jinfukang | decreases expression | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Arsenic | affects cotreatment, increases abundance, increases expression | 1 |
| Benzo(a)pyrene | decreases methylation | 1 |
| Cadmium | decreases expression, increases abundance | 1 |
| Caffeine | increases phosphorylation | 1 |
| Enzyme Inhibitors | decreases activity, increases O-linked glycosylation | 1 |
| Ivermectin | decreases expression | 1 |
| Manganese | increases abundance, increases expression, affects cotreatment | 1 |
| Mustard Gas | increases phosphorylation | 1 |
| Phenobarbital | affects expression | 1 |
| Quercetin | decreases expression | 1 |
| Ribonucleotides | affects binding | 1 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B2W0 | Abcam HEK293T DNAJC2 KO | Transformed cell line | Female |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.